

COMPARATIVE STUDY OF SURGICAL LIGATION AND STRIPPING VERSUS ULTRASOUND GUIDED FOAM SCLEROTHERAPY IN THE MANAGEMENT OF PRIMARY VARICOSE VEINS

Abstract:

Background: Characterized by dilated, tortuous superficial veins, primary varicose veins represent a common and often debilitating chronic venous disorder. For decades, surgical ligation and stripping (SLS) has been considered the traditional gold standard for the definitive management of symptomatic primary varicose veins. In response to the desire for less invasive treatment modalities and driven by technological advancements, ultrasound-guided foam sclerotherapy (UGFS) has emerged as a widely adopted alternative for primary varicose veins.

Methods: A prospective, observational study was conducted among 120 subjects which compared surgical stripping (n=60) versus ultrasound-guided foam sclerotherapy (n=60) for primary varicose veins. Procedures were detailed. Outcomes including Venous Clinical Severity Score, recurrence, complications and satisfaction were assessed at 1, 3, 6, 12 months. A p value of <0.05 was considered statistically significant.

Results: Both treatments improved VCSS scores, but the UGFS group had higher scores at day 7 (p=0.029). In the first week, surgical patients had increased discomfort. After one month, UGFS reported increased pain ratings. The two groups' mean varicosity assessments did not alter much after treatment. VDS scores improved considerably for the UGFS group at 7 days. At 1- and 3-month follow-ups, the surgical group had higher VDS scores. The surgical group had higher seventh-day problems such as discomfort, bruising, stitch infection, seroma, and hematoma.

Conclusion: Foam sclerotherapy has emerged as a safe, promising, and dependable treatment for varicose veins, characterized by convenience of administration, no need for hospital admission, absence of anaesthetic risks, little disruption to daily activities, fast return to work, and comparable efficacy to surgical intervention.

Keywords: Sclerotherapy, Varicose vein, Stripping, Pigmentation, Insufficiency

INTRODUCTION

Primary varicose veins represent a common and often debilitating chronic venous disorder, affecting a substantial portion of the adult population globally, with prevalence estimates ranging from 10% to 30%.^(1,2) Characterized by dilated, tortuous superficial veins, this condition typically arises from valvular incompetence within the superficial venous system, predominantly involving the great saphenous vein (GSV) or small saphenous vein (SSV).⁽³⁾ Beyond cosmetic concerns, varicose veins can lead to a spectrum of symptoms including pain, heaviness, itching, swelling, and cramping, which significantly impair a patient's quality of life. Progression of the disease can result in more severe complications such as skin changes, thrombophlebitis, venous ulceration, and even bleeding, posing considerable healthcare burdens.⁽⁴⁾

For decades, surgical ligation and stripping (SLS) has been considered the traditional gold standard for the definitive management of symptomatic primary varicose veins.⁽⁵⁾ This invasive procedure involves the surgical disconnection of the saphenofemoral or saphenopopliteal junction (ligation) and the physical removal of the incompetent saphenous vein (stripping). While demonstrably effective in eliminating the refluxing segment and alleviating symptoms, SLS is associated with potential drawbacks such as general anesthesia requirements, larger incisions, longer recovery times, significant post-operative pain, ecchymosis, and a risk of complications including nerve injury, hematoma, and infection.^(6,7)

In response to the desire for less invasive treatment modalities and driven by technological advancements, ultrasound-guided foam sclerotherapy (UGFS) has emerged as a widely adopted alternative for primary varicose veins.⁽⁸⁾ This endovenous technique involves injecting a sclerosant mixed with air to form a foam directly into the incompetent vein segment under ultrasound guidance. The foam displaces blood, allowing the sclerosant to contact the vein wall, causing endothelial damage, fibrosis, and eventual occlusion of the vein. UGFS offers several advantages over traditional surgery, including being a minimally invasive, office-based procedure, often performed under local anesthesia, with reduced recovery time and potentially fewer immediate complications.⁽⁹⁾

Despite the growing popularity and perceived benefits of UGFS, a robust body of comparative evidence is essential to critically evaluate its efficacy, safety profile, and long-term outcomes relative to the established SLS. While numerous studies have reported

promising short-to-medium term results for UGFS, concerns regarding its long-term recurrence rates, potential for skin staining, and varying efficacy based on foam concentration and injection technique remain.(10,11) Conversely, improvements in surgical techniques and perioperative care continue to refine the outcomes of SLS. Therefore, a comprehensive comparative study is imperative to provide clearer guidance for clinical practice, aiding surgeons and patients in making informed decisions regarding the optimal management strategy for primary varicose veins. This study aims to directly compare the clinical efficacy, recurrence rates, complication profiles, and patient satisfaction between surgical ligation and stripping and ultrasound-guided foam sclerotherapy in the management of primary varicose veins.

MATERIALS AND METHODS

Study Design and Setting

This was a prospective, observational study conducted at a tertiary care hospital. The study was initiated following the ethical committee approval and after obtaining written informed consent from the study participants. Patients diagnosed with symptomatic primary varicose veins meeting the eligibility criteria were randomly allocated into two parallel groups to receive either surgical high ligation and stripping or ultrasound-guided foam sclerotherapy. The study aimed to compare the clinical outcomes, recurrence rates, complication profiles, and patient satisfaction between these two treatment modalities over a 12-month follow-up period.

A total of 120 patients diagnosed with primary varicose veins were enrolled in the study. Patients were randomly allocated into two equal groups: Group A (n=60): Underwent high ligation and great saphenous vein stripping. Group B (n=60): Received ultrasound-guided foam sclerotherapy (UGFS).

Patient selection

Inclusion criteria

1. All adults (>18 years of age) clinically diagnosed with primary varicose veins (C2-C4 based on the CEAP classification) and willing to participate in this research were included in the study.

Exclusion criteria

1. Varicose veins due to a history of deep vein thrombosis (post-thrombotic syndrome), arteriovenous fistulae, or pelvic congestion syndrome.
2. History of previous surgery, sclerotherapy, or endogenous thermal ablation for varicose veins in the limb designated for the study
3. Pregnancy or lactation
4. Coagulopathies, severe systemic diseases, uncontrolled diabetes mellitus
5. Severe cardiac failure, severe renal or hepatic impairment
6. Active malignancy, or other life-limiting comorbidities
7. Severe arterial disease
8. Thrombophilia

UNDER PEER REVIEW IN IJAR

Methodology:

Group A: High Ligation and Great Saphenous Vein Stripping

Detailed duplex ultrasound mapping of the entire saphenous system, limb marking, and pre-operative assessment were performed. The procedure involved a groin incision for high ligation of the GSV at the saphenofemoral junction with division of tributaries, followed by stripping of the incompetent GSV segment (typically to the knee or mid-calf) using an intraluminal stripper. Compression bandaging was applied immediately post-surgery, gradual ambulation was encouraged, and analgesics were prescribed. Patients were advised to wear graduated compression stockings for a specified period (e.g., 4-6 weeks).

Group B: Ultrasound-Guided Foam Sclerotherapy (UGFS)

Detailed duplex ultrasound mapping of the entire saphenous system and limb marking were performed. Polidocanol foam was prepared using the Tessari method (1 part polidocanol to 4 parts air) immediately prior to injection. The foam was injected directly into the incompetent saphenous vein segment under continuous real-time ultrasound guidance, starting from the most proximal point of reflux. Digital compression was applied distal to the injection site to aid foam distribution. Immediate compression bandaging and application of graduated compression stockings were carried out. Patients were encouraged to ambulate immediately. Post-procedure ultrasound was performed within 24-48 hours to confirm occlusion and rule out DVT.

Baseline demographic data and clinical characteristics were recorded for all patients. Follow-up assessments were conducted at 1, 3, 6, and 12 months post-procedure. The Venous Clinical Severity Score was assessed at each follow-up visit. This validated, 10-item questionnaire covered pain, oedema, claudication, skin changes, and ulceration, providing a quantitative measure of disease severity and treatment effectiveness.

Statistical analysis

Data were entered into a Microsoft excel and analyzed using SPSS v27.0. Baseline characteristics between the two groups were compared using independent t-tests for continuous variables and Chi-square tests for categorical variables. A p-value < 0.05 was considered statistically significant.

RESULTS

The mean age of the study population in group A was 38.42 ± 8.45 years and in group B was 35.64 ± 11.42 years. In the group A there were 57 (95.0%) males and in group B there were 54 (90.0%) males.

Figure 1: Mean age of the study population





Figure 2: Gender distribution of the study population




Both treatment methods shown comparable efficacy in enhancing VCSS scores, with the UGFS group showing better VCSS scores at 7th post operative day (p=0.029).

Table 1: Comparison of mean VCSS scores in both the groups

VCSS Score	Group A (N = 60)	Group B (N = 60)	P value
Pre Op	7.63 ± 2.14	7.79 ± 3.14	0.893
7th day post Op	4.31 ± 2.50	3.25 ± 1.15	0.029
1 month post Op	1.84 ± 1.02	1.44 ± 1.32	0.749
3-month post Op	1.78 ± 0.87	1.37 ± 0.89	0.169

149 Figure 3: Graph representing mean VCSS scores in both the groups



150

151 Table 2: Change of mean VCSS scores in both the groups

VCSS Score	Group A (N = 60)		P value	Group B (N = 60)		P value
	Before	After		Before	After	
7th day	7.63 ± 2.14	4.31 ± 2.50	<0.001	7.79 ± 3.14	3.25 ± 1.15	<0.001
1 month	7.63 ± 2.14	1.84 ± 1.02	<0.001	7.79 ± 3.14	1.44 ± 1.32	<0.001
3 month	7.63 ± 2.14	1.78 ± 0.87	<0.001	7.79 ± 3.14	1.37 ± 0.89	<0.001

152

153 Looking at pain scores it was observed that, preoperative pain scores were similar in both the
 154 groups. Post procedure the pain was found to be more in the surgery group compared to the
 155 UGFS group during the first week. Later at one month, the pain scores were found to be
 156 higher in group B following UGFS.

157 Considering the varicosity score, pre-operative ratings were not similar, and the Surgical
 158 group had a higher number of patients with significant varicosities in their legs (p = 0.001).
 159 Following therapy, there was no statistically significant change in mean varicosity ratings

between the two groups. Varicosity ratings decreased markedly in both groups before and after therapy ($p < 0.000$)

Venous oedema was found to be resolved satisfactorily in both the groups post the procedure. But there was no statistically significant difference in the venous oedema scores in both the groups ($p = 0.584$). But the odema scores reduced significantly in both the groups before and after the treatment.

Pigmentation score was found to be better in the UGFS groups at one month ($p = 0.041$) and at three months ($p = 0.04$) compared to the surgery group.

The need for compression stockings in both groups was same pre-operatively ($p = 0.847$) and until the seventh post-treatment day ($p = 0.247$). At the one-month follow-up, a substantially greater number of patients in the UGFS group were using compression therapy ($p = 0.024$).


Venous disability score

The VDS scores were similar in both groups prior to the initiation of therapy ($p = 0.823$). The UGFS group exhibited substantially superior enhancements in VDS scores at the first follow-up on the seventh day ($p = 0.014$). However, by the conclusion of one and three months, the scores favoured individuals who had surgery ($p = 0.042$ and 0.012 respectively) (Table 3). VDS scores were markedly decreased in both groups ($p < 0.001$).

Table 3: Mean VDS scores in both the groups

VDS scores	Group A (n = 60)	Group B (n = 60)	P value
Pre op	1.36 ± 0.28	1.44 ± 0.36	0.823
7th day post op	0.84 ± 0.31	0.41 ± 0.20	0.014
1 month post op	0.20 ± 0.02	0.24 ± 0.08	0.042
3-month post op	0.08 ± 0.04	0.18 ± 0.06	0.012

Figure 4: Comparison of mean VDS scores in both the groups



The mean procedure time for group A was 110.34 ± 14.23 but the mean time in case of group B (UGFS) was 32.4 ± 3.36 mins. This difference in mean time of the procedure was statistically significant. The mean hospital stay was also found to be higher in group A (35.2 ± 4.54 hours) compared to group B (2.4 ± 0.6 hours). This difference was also statistically significant.

The patients in the surgical group resumed their daily activities after a mean of 8.6 ± 2.3 days, whereas those in the UGFS group returned to work the next day ($p < 0.001$). The average analgesic required in the surgical group was 4.21 ± 1.9 days, but in the UGFS group it was 0.84 ± 0.65 days ($p < 0.001$).

Early complications seen on the seventh post-operative day, including pain, bruising, stitch infection, seroma, and hematoma, were more prevalent in the surgical group. Late complications seen at the 1-month and 3-month follow-ups included discomfort, pigmentation and neuralgia. No DVT was identified; the other complications were minimal and equivalent across both groups.

197 **DISCUSSION**

198 This study was conducted among 120 subjects to compare the clinical efficacy, recurrence
199 rates, complication profiles, and patient satisfaction between surgical ligation and stripping
200 and ultrasound-guided foam sclerotherapy in the management of primary varicose veins. The
201 majority of the subjects in the study were males. This is similar to the study conducted by
202 Jain et al., and Masuda et al., where almost 97.6% and 61.7% were males respectively.(12,13)
203 But most of the foreign authors report a higher prevalence of the disease in females.(14–18)

204 The majority of our patients were young, with a mean age of 38.42 ± 8.45 years in group A
205 and was 35.64 ± 11.42 years in group B. This is lower compared to the majority of patients in
206 the western world, where most appear in their late 50s and early 60s.(19,20) The increased
207 involvement of men in heavy work which requires prolonged standing may account for the
208 predominance of younger male patients afflicted with the condition.

209 A study conducted by Kakkos et al., indicated that VCSS, VDS, and CEAP clinical scores
210 exhibited comparable sensitivity and were superior for assessing responses to superficial
211 venous surgery.(21) Limited randomized studies have compared UGFS with surgical
212 interventions.(15,16) In our study, the mean VCSS scores for the disease were analogous in
213 both groups prior to treatment initiation. Both treatment modalities demonstrated equivalent
214 efficacy in enhancing the VCSS score at 1 and 3 months; however, patients undergoing
215 UGFS exhibited more significant improvements in total VCSS scores during the early
216 postoperative period at day 7.

217 In the research conducted by Masuda EM et al., they analysed the alteration in VCSS after
218 foam sclerotherapy and observed that the median score shifted from 8 to 2, indicating a 75%
219 change in score.(13) Iafrati MD et al., compared the alteration in VCSS post-surgery and
220 determined that the mean VCSS shifted from 9.8 to 4.2, indicating a 57% decrease in
221 score.(22) Gloviczki P et al., also analyzed the alteration in VCSS post-surgery and
222 determined that the mean VCSS shifted from 8.93 to 3.98, reflecting a 55% change in score
223 after the therapy.(23) Nevertheless, there is little information explicitly comparing UGFS
224 with surgery based on VCSS and VDS.

225 Figueiredo M et al. evaluated the outcomes of foam sclerotherapy and surgery based on the
226 Venous Clinical Severity Score (VCSS). He considers just the mean score change in the three
227 components of VCSS—pain, oedema, and inflammation—without accounting for the overall
228 score change. They observed a significant improvement in the average score of each

aforementioned component of VCSS in both groups.(15) Our investigation revealed that both techniques were equally helpful in alleviating oedema and discomfort post-treatment.

The literature reveals a scarcity of data to compare the three parameters studied: varicosity, pigmentation, and compression treatment scores. The pigmentation score did not exhibit substantial improvement in consecutive follow-ups. The underlying cause is that skin alterations and lipodermatosclerosis associated with varicose veins are permanent changes, and any substantial improvement requires an extended duration. The need for compression treatment saw substantial alteration within the surgical cohort.

The functional capacity evaluated by VDS indicated that both modalities shown considerable improvement post-treatment and were equally effective. The results were unequivocally inferior to those documented in the research by Masuda et al.(13) This was likely due to the score's heavy reliance on the patient's capacity to do activities. The majority of our patients were daily wage workers who prioritized resuming activities promptly to sustain their families.

Our investigation shown that UGFS required much less time than standard surgery. Additionally, our foam sclerotherapy was an outpatient operation. This parallels other studies that have shown a much shorter duration for UGFS compared to surgical procedures.(15–17,24)

Certain complications were exclusive to the surgical group and not seen in the UGFS group. Complications included suture infection, seroma and hematoma during the one-week follow-up. Figueiredo M et al., during 2009 report infection, hematoma, and suture dehiscence in the surgical cohort at rates of 3%, 7%, and 38%, respectively.(15) In contrast to the findings of Michaels JA et al., who reported a local wound-related complication rate of just 2.4% among patients, our research group exhibited a higher incidence of such issues.(16)

In our research, problems in the foam sclerotherapy group were manageable and temporary, such as pain when walking and soreness, and did not need any active intervention, aligning with previous reports.(25–27) Pain and pigmentation were the two primary complications in the foam group in our investigation, consistent with the literature. No significant complications were identified in the UGFS group, as corroborated by existing research. Foam sclerotherapy is a relatively safe operation when performed with appropriate ultrasound guidance and meticulous attention.(25–27)

Following foam sclerotherapy, almost all patients were released on the same day following a brief observation period. Following the surgical procedure the patients were discharged only after one day of observation. Iafrati et al. released their patients after 1.3 days.(22) Jain et al released their patients after an average period of 4.5 days, however the rationale for this duration was not provided in the literature.(12)

The mean time to return to regular activities in our research was 8.6 ± 2.3 days for the surgery group and 1 day for the foam group. Bountouroglou DG et al., indicate that the average duration for resuming normal activities was 8 days for the surgical group and 2 days for the foam group.(18) This is very similar to our discovery. Darvall KL et al., discovered that over 50.0% of patients undergoing foam sclerotherapy resumed work within 24 hours, while surgical patients typically required about 4 days to return to work.(24)

The average analgesic required in the surgical group was 4.21 ± 1.9 days, but in the UGFS group it was 0.84 ± 0.65 days. Abela R et al. discovered that 83.0% of patients having conventional surgery need postoperative analgesia, but only 23.0% of patients receiving foam sclerotherapy sometimes required analgesia postoperatively.(17) Darvall KA et al. discovered that after foam sclerotherapy, 70.8% of patients needed no analgesics, in contrast to 24.0% after surgery during the early postoperative period. After one week, only 4.1% of participants in the foam sclerotherapy group continued to need analgesia, in contrast to 30% in the surgery group.(24)

We have conducted doppler follow-up for all patients one month post-operatively. At one month post-operatively, we saw no instances of deep vein thrombosis (DVT) in either group and recorded a 100% obliteration rate of the greater saphenous vein (GSV). Figueiredo M et al. report an obliteration rate of 90% in the surgical group and 78% in the foam sclerotherapy group after six months of follow-up.(15) Bountouroglou DG et al. reported an obliteration rate of 89% in the surgical group and 78% in the foam sclerotherapy group after 12 months of follow-up.(18) The elevated obliteration rate seen in our research may be attributed to the short follow-up duration relative to the aforementioned studies, as well as the use of catheter-guided foam sclerotherapy, which is more effective than traditional sclerotherapy.

CONCLUSION

Foam sclerotherapy has emerged as a safe and effective treatment for varicose veins. This requires no additional setup beyond a Doppler, since duplex ultrasound facilities are accessible at all major hospitals, making the procedure cost-effective. UGFS may be performed as an outpatient procedure under local anesthetic, hence significantly reducing costs and hospital duration. The therapeutic outcomes, including immediate post-procedure problems, enhancements in severity/disability ratings, recurrence rates, and overall clinical and radiological results, are equivalent to those of surgical care. The treatment was exceptionally gratifying for patients due to its straightforward administration, absence of hospital admission, lack of anesthetic danger, affordability, non-disruption of everyday activities, prompt return to work, and results closely like those of surgical procedures. The method was well tolerated both locally and systemically, with no significant problems, and was very acceptable to the patients. Nonetheless, it is essential to conduct studies including a larger cohort of patients with extended follow-up to reach any definitive conclusions on the potential of this therapy as the gold standard treatment in the future.

REFERENCES

1. Youn YJ, Lee J. Chronic venous insufficiency and varicose veins of the lower extremities. *Korean J Intern Med.* 2019 Mar 1;34(2):269–83.
2. Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. *J Vasc Surg.* 2011 May;53(5):2S-48S.
3. Bergan JJ, Schmid-Schönbein GW, Smith PDC, Nicolaides AN, Boisseau MR, Eklof B. Chronic Venous Disease. *New England Journal of Medicine.* 2006 Aug 3;355(5):488–98.
4. Branisteanu DE, Feodor T, Baila S, Mitea IA, Vittos O. Impact of chronic venous disease on quality of life: Results of vein alarm study. *Exp Ther Med.* 2018 Dec 5;
5. Jaworucka-Kaczorowska A, Oszkinis G, Huber J, Wiertel-Krawczuk A, Gabor E, Kaczorowski P. Saphenous vein stripping surgical technique and frequency of saphenous nerve injury. *Phlebology: The Journal of Venous Disease.* 2015 Apr 6;30(3):210–6.
6. Alozai T, Huizing E, Schreve M, Mooij MC, van Vlijmen CJ, Wisselink W, et al. A systematic review and meta-analysis of mechanochemical endovenous ablation using Flebogrif for varicose veins. *J Vasc Surg Venous Lymphat Disord.* 2022 Jan;10(1):248-257.e2.
7. Brittenden J, Cotton SC, Elders A, Tassie E, Scotland G, Ramsay CR, et al. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial. *Health Technol Assess (Rockv).* 2015 Apr;19(27):1–342.
8. Coleridge Smith P. Sclerotherapy and foam sclerotherapy for varicose veins. *Phlebology: The Journal of Venous Disease.* 2009 Dec 1;24(6):260–9.
9. Cartee T V., Wirth P, Greene A, Straight C, Friedmann DP, Pittman C, et al. Ultrasound-guided foam sclerotherapy is safe and effective in the management of

superficial venous insufficiency of the lower extremity. *J Vasc Surg Venous Lymphat Disord.* 2021 Jul;9(4):1031–40.

10. Kalodiki E, Lattimer CR, Azzam M, Shawish E, Bountouroglou D, Geroulakos G. Long-term results of a randomized controlled trial on ultrasound-guided foam sclerotherapy combined with saphenofemoral ligation vs standard surgery for varicose veins. *J Vasc Surg.* 2012 Feb;55(2):451–7.

11. Murad MH, Coto-Yglesias F, Zumaeta-Garcia M, Elamin MB, Duggirala MK, Erwin PJ, et al. A systematic review and meta-analysis of the treatments of varicose veins. *J Vasc Surg.* 2011 May;53(5):49S-65S.

12. Jain SK, Gupta A, Murti Kaza RC. Use of Ultrasonic Scalpel in Subfascial Endoscopic Perforator Vein Surgery: A Novel Approach. *Journal of Laparoendoscopic & Advanced Surgical Techniques.* 2008 Apr;18(2):244–7.

13. Masuda EM, Kessler DM, Lurie F, Puggioni A, Kistner RL, Eklof B. The effect of ultrasound-guided sclerotherapy of incompetent perforator veins on venous clinical severity and disability scores. *J Vasc Surg.* 2006 Mar;43(3):551–7.

14. Winterborn R, Corbett C. Treatment of Varicose Veins: The Present and the Future – A Questionnaire Survey. *The Annals of The Royal College of Surgeons of England.* 2008 Oct;90(7):561–4.

15. Figueiredo M, Araújo S, Barros N, Miranda F. Results of Surgical Treatment Compared with Ultrasound-Guided Foam Sclerotherapy in Patients with Varicose Veins: A Prospective Randomised Study. *European Journal of Vascular and Endovascular Surgery.* 2009 Dec;38(6):758–63.

16. Michaels J, Campbell W, Brazier J, MacIntyre J, Palfreyman S, Ratcliffe J, et al. Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial). *Health Technol Assess (Rockv).* 2006 Apr;10(13).

17. Abela R, Liamis A, Prionidis I, Mathai J, Gorton L, Browne T, et al. Reverse Foam Sclerotherapy of the Great Saphenous Vein with Sapheno-Femoral Ligation Compared to Standard and Invagination Stripping: a Prospective Clinical Series. *European Journal of Vascular and Endovascular Surgery.* 2008 Oct;36(4):485–90.

- 366 18. Bountouroglou DG, Azzam M, Kakkos SK, Pathmarajah M, Young P, Geroulakos G.
367 Ultrasound-guided Foam Sclerotherapy Combined with Sapheno-femoral Ligation
368 Compared to Surgical Treatment of Varicose Veins: Early Results of a Randomised
369 Controlled Trial. *European Journal of Vascular and Endovascular Surgery*. 2006
370 Jan;31(1):93–100.
- 371 19. van den Bremer J, Moll FL. Historical Overview of Varicose Vein Surgery. *Ann Vasc*
372 *Surg*. 2010 Apr;24(3):426–32.
- 373 20. Dwerryhouse S, Davies B, Harradine K, Earnshaw JJ. Stripping the long saphenous
374 vein reduces the rate of reoperation for recurrent varicose veins: Five-year results of a
375 randomized trial. *J Vasc Surg*. 1999 Apr;29(4):589–92.
- 376 21. Kakkos SK, Rivera MA, Matsagas MI, Lazarides MK, Robless P, Belcaro G, et al.
377 Validation of the new venous severity scoring system in varicose vein surgery. *J Vasc*
378 *Surg*. 2003 Aug;38(2):224–8.
- 379 22. Iafrati MD, Pare GJ, O'Donnell TF, Estes J. Is the nihilistic approach to surgical
380 reduction of superficial and perforator vein incompetence for venous ulcer justified? *J*
381 *Vasc Surg*. 2002 Dec;36(6):1167–74.
- 382 23. Gloviczki P, Bergan JJ, Rhodes JM, Canton LG, Harmsen S, Ilstrup DM, et al. Mid-
383 term results of endoscopic perforator vein interruption for chronic venous
384 insufficiency: Lessons learned from the North American Subfascial Endoscopic
385 Perforator Surgery registry. *J Vasc Surg*. 1999 Mar;29(3):489–502.
- 386 24. Darvall KAL, Bate GR, Adam DJ, Bradbury AW. Recovery after ultrasound-guided
387 foam sclerotherapy compared with conventional surgery for varicose veins. *British*
388 *Journal of Surgery*. 2009 Oct 21;96(11):1262–7.
- 389 25. Jia X, Mowatt G, Burr JM, Cassar K, Cook J, Fraser C. Systematic review of foam
390 sclerotherapy for varicose veins. *British Journal of Surgery*. 2007 Jul 16;94(8):925–36.
- 391 26. Ouvry P, Allaert FA, Desnos P, Hamel-Desnos C. Efficacy of Polidocanol Foam versus
392 Liquid in Sclerotherapy of the Great Saphenous Vein: A Multicentre Randomised
393 Controlled Trial with a 2-year Follow-up. *European Journal of Vascular and*
394 *Endovascular Surgery*. 2008 Sep;36(3):366–70.

395 27. Guex JJ, Schliephake DE, Otto J, Mako S, Allaert FA. The French Polidocanol Study
396 on Long-Term Side Effects. Dermatologic Surgery. 2010 Jun;36(Sup 2):993–1003.

397

UNDER PEER REVIEW IN IJAR